Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation

Molecular and Cellular Biology

Volumn 18, Issue 9, 1998, Pages 5208-5218

  Gale Jr , Michael ^a   Blakely, Collin M ^b   Kwieciszewski, Bart ^b   Tan, Seng Lai ^a   Dossett, Michelle ^a   Tang, Norina M ^a   Korth, Marcus J ^b   Polyak, Stephen J ^b   Gretch, David R ^b   Katze, Michael G ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PROTEIN KINASE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; DIMERIZATION; ENZYME ACTIVITY; ENZYME REGULATION; HEPATITIS C VIRUS; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS;

DNA VIRUSES; HEPATITIS C VIRUS; MAMMALIA;

EID: 17144463221     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.9.5208     Document Type: Article

References (79)

1. Alter, M. 1995. Epidemiology of hepatitis C in the west. Semin. Liver Dis. 15:5-14.
2. Barber, G. N., R. Jagus, E. F. Meurs, A. G. Hovanessian, and M. G. Katze. 1995. Molecular mechanisms responsible for malignant transformation by regulatory and catalytic domain variants of the interferon-induced enzyme RNA-dependent protein kinase. J. Biol. Chem. 270:17423-17428.
3. Barber, G. N., S. Thompson, T. G. Lee, T. Strom, R. Jagus, A. Darveau, and M. G. Katze. 1994. The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties. Proc. Natl. Acad. Sci. USA 91:4278-4282.
4. Barber, G. N., M. Wambach, S. Thompson, R. Jagus, and M. G. Katze. 1995. Mutants of the RNA-dependent protein kinase (PKR) lacking double- stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol. Cell. Biol. 15:3138-3146.
5. Barber, G. N., M. Wambach, M.-L. Wong, T. E. Dever, A. G. Hinnebusch, and M. G. Katze. 1993. Translational regulation by the interferon-induced double-stranded-RNA-activated 68-kDa protein kinase. Proc. Natl. Acad. Sci. USA 90:4621-4625.
6. Bartel, P. L., C.-T. Chien, R. Sternglanz, and S. Fields. 1993. Using the two-hybrid system to detect protein-protein interactions, p. 153-179. In D. A. Hartley (ed.), Cellular interactions in development: a practical approach. Oxford University Press, Oxford, England.
7. Benkirant, M., C. Neuveut, R. F. Chun, S. M. Smith, C. E. Samuel, A. Gatignol, and K.-T. Jeang. 1997. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 16:611-624.
8. Borowski, P., K. Oehlmann, M. Heiland, and R. Laufs. 1997. Nonstructural protein 3 of hepatitis C virus blocks the distribution of free catalytic subunit of cyclic AMP-dependent protein kinase. J. Virol. 71:2838-2843.
9. Carpick, B. W., V. Graziano, D. Schneider, R. K. Maitra, X. Lee, and B. R. G. Williams. 1997. Characterization of the solution structure between the interferon-induced double-stranded RNA-activated protein kinase and HIV-1 transactivating region RNA. J. Biol. Chem. 272:9510-9516.
10. Cesareni, G., and J. A. H. Murray. 1987. Plasmid vectors carrying the replication origin of filamentous single-stranded phages, p. 135-154. In J. K. Setlow (ed.), Genetic engineering: principles and methods. Plenum Press, New York, N.Y.
11. Chang, J., S.-H. Yang, Y.-G. Cho, S. B. Hwang, Y. S. Hahn, and Y. C. Sung. 1998, Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene. J. Virol. 72:3060-3065.
12. Chayama, K., A. Tsubota, M. Kobayashi, K. Okamoto, M. Hashimoto, Y. Miyano, H. Koike, I. Koida, Y. Arase, S. Saitoh, Y. Suzuki, N. Murashima, K. Ikeda, and H. Kumada. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.
13. Clemens, M. J., and A. Elia. 1997. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Cytokine Res. 17:503-524.
14. Clements, J. E., and M. C. Zink. 1996. Molecular biology and pathogenesis of animal lentivirus infections. Clin. Microbiol. Rev. 9:100-117.
15. Cosentino, G. P., S. Venkatesan, F. C. Serluca, S. R. Green, M. B. Mathews, and N. Sonenberg. 1995. Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo. Proc. Natl. Acad. Sci. USA 92:9445-9449.
16. Craig, A. W., G. P. Cosentino, O. Donzé, and N. Sonenberg. 1996. The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L. J. Biol. Chem. 271:24526-24533.
17. Cuthbert, J. A. 1994. Hepatitis C: progress and problems. Clin. Microbiol. Rev. 7:505-532.
18. Der, S. D., Y.-L. Yang, C. Weissman, and B. R. G. Williams. 1997. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:3279-3283.
19. Dever, T. E., J.-J. Chen, G. N. Barber, A. M. Cigan, L. Feng, T. F. Donahue, I. M. London, M. G. Katze, and A. G. Hinnebusch. 1993. Mammalian eukaryotic initiation factor eIF2α kinases functionally substitute for GCN2 protein kinase in the GCN4 translational control mechanism of yeast. Proc. Natl. Acad. Sci. USA 90:4616-4620.
20. Di Bisceglie, A. M. 1995. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis. 15:64-69.
21. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Maruno, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:77-81.
22. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murankami, C. Yamamoto, N. Izumi, F. Marumo, and C. Sato. 1995. Comparison of full- length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J. Clin. Investig. 96:224-230.
23. Fried, M., and J. Hoofnagle. 1995. Therapy of hepatitis C. Semin. Liver Dis. 15:82-91.
24. Gale, M., Jr., and M. G. Katze. 1998. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon- induced protein kinase. Pharmacol. Ther. 78:29-46.
25. IPK and vaccinia virus K3L is mediated by unique domains: implications for kinase regulation. Mol. Cell. Biol. 16:4172-4181.
26. rIPK. Mol. Cell. Biol. 18:859-871.
27. Gale, M., Jr., M. J. Korth, N. M. Tang, S. L. Tan, D. A. Hopkins, T. E. Dever, S. J. Polyak, D. R. Gretch, and M. G. Katze. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
28. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
29. Herion, D., and J. Hoofnagle. 1997. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 25:769- 771.
30. Hofgärtner, W. T., S. J. Polyak, D. Sullivan, R. L. Carithers, Jr., and D. R. Gretch. 1997. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J. Med. Virol. 53:118-126.
31. Houghton, M., A. Weiner, J. Han, G. Kuo, and Q.-L. Choo. 1991. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14:381-388.
32. Hu, J. C. 1995. Repressor fusions as a tool to study protein-protein interactions. Structure 3:431-433.
33. Hu, J. C., E. K. O'Shea, P. S. Kim, and R. T. Saur. 1990. Sequence requirements for coiled-coils: analysis with lambda repressor-GCN4 leucine zipper fusions. Science 250:1400-1403.
34. Ide, Y., A. Tanimoto, Y. Sasaguri, and R. Padmanabhan. 1997. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. Gene 201:151-158.
35. Kaneko, T., Y. Tanji, S. Satoh, M. Hgikata, S. Asabe, K. Kimura, and K. Shimotohno. 1994. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205:320-326.
36. Kato, N., M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, T. Sugimura, and K. Shimotohno. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA 87:9524-9528.
37. Katze, M. G. 1992. The war against the interferon-induced dsRNA-activated protein kinase: can viruses win? J. Interferon Res. 12:241-248.
38. r protein kinase in a cell-free system. Mol. Cell. Biol. 11:5497- 5505.
39. Kawagishi-Kobayashi, M., J. B. Silverman, T. L. Ung, and T. E. Dever. 1997. Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF-2α. Mol. Cell. Biol. 17:4146-4158.
40. Khorsi, H., S. Castelain, A. Wyseur, J. Izopet, V. Canva, A. Rombout, D. Capron, J.-P. Capron, F. Lunel, L. Stuyver, and G. Duverlie. 1997. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alpha therapy in French patients. J. Hepatol. 27:72-77.
41. Kolykhalov, A. A., E. V. Agapov, K. J. Blight, K. Mihalik, S. M. Feinstone, and C. M. Rice. 1997. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574.
42. Koromilas, A. E., S. Roy, G. N. Barber, M. G. Katze, and N. Sonenberg. 1992. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257:1685-1689.
43. Kumar, A., J. Haque, J. Lacoste, J. Hiscott, and B. R. G. Williams. 1994. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc. Natl. Acad. Sci. USA 91:6288- 6292.
44. Kumar, A., Y.-L. Yang, V. Flati, S. Der, S. Kadereit. A. Deb, J. Haque, L. Reis, C. Weissmann, and B. R. G. Williams. 1997. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-κB. EMBO J. 16:406-416.
45. Kurosaki, M., N. Enomoto, T. Murakami, I. Sakuma, Y. Asahina, C. Yamamoto, T. Ikeda, S. Tozuka, N. Izumi, F. Marumo, and C. Sato. 1997. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy. Hepatology 25:750-753.
46. r 66,000 subunits. J. Biol. Chem. 267:10729-10736.
47. Laurent, A. G., B. Krust, J. Galabru, J. Svab, and A. G. Hovanessian. 1985. Monoclonal antibodies to interferon induced 68,000 Mr protein and their use for the detection of double-stranded RNA dependent protein kinase in human cells. Proc. Natl. Acad. Sci. USA 82:4341-4345.
48. Lee, T. G., N. Tang, S. Thompson, J. Miller, and M. G. Katze. 1994. The 58,000-Dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins. Mol. Cell. Biol. 14:2331-2342.
49. Mansell, C., and S. Locarnini. 1995. Epidemiology of hepatitis C in the east. Semin. Liver Dis. 15:15-32.
50. Matsumoto, M., T.-Y. Hsieh, N. Zhu, T. VanArsdale, S. B. Hwang, A. E. Gorbalenya, S.-Y. Lo, J.-H. Ou, C. F. Ware, and M. C. Lai. 1997. Hepatitis C virus core protein interacts with the cytoplasmic tail of the Iymphotoxin-β receptor. J. Virol. 71:1301-1309.
51. Merrick, W. C., and J. W. B. Hershey. 1996. The pathway and mechanism of eukaryotic protein synthesis, p. 31-70. In J. Hershey, M. Mathews, and N. Sonenberg (ed.), Translational control. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, N.Y.
52. Meurs, E., K. L. Chong, J. Galabru, N. Thomas, I. Kerr, B. R. G. Williams, and A. G. Hovanessian. 1990. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379-390.
53. Meurs, E., Y. Watanabe, G. N. Barber, M. G. Katze, K. L. Chong, B. R. G. Williams, and A. G. Hovanessian. 1992. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phos- phorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66:5805-5814.
54. Meurs, E. F., J. Galabru, G. N. Barber, M. G. Katze, and A. G. Hovanessian. 1993. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 90:232-236.
55. Ortega, L. G., M. D. McCotter, G. L. Henry, S. J. McCormack, D. C. Thomis, and C. E. Samuel. 1996. Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA-dependent protein kinase PKR from human cells. Virology 215:31-39.
56. Patel, R. C-. P. Stanton, and G. C. Sen. 1994. Role of the amino-lerminal residues of the interferon-induced protein kinase in its activation by double- stranded RNA and heparin. J. Biol. Chem. 269:18593-18598.
57. Patel. R. C., P. Stanton, and G. C. Sen. 1996. Specific mutations near the amino terminus of double-stranded RNA-dependent protein kinase (PKR) differentially affect its double-stranded RNA binding and dimerization properties. J. Biol. Chem. 271:25657-25663.
58. Polyak, S. J., S. McCardle, S.-L. Lui, D. Sullivan, M. Chung, W. T. Hofgärtner, R. Carithers, B. J. McMahon, J. I. Mullins, L. Corey, and D. R. Gretch. 1998. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interieron sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72:4288-4296.
59. Proud, C. G. 1995. PKR: a new name and new roles. Trends Biochem. Sci. 20:241-246.
60. Ray. R. B., K. Meyer, and R. Ray. 1996. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226:176-182.
61. Ray, R. B., L. M. Lagging, K. Meyer, and R. Ray. 1996. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70:4438-4443.
62. Reed, K. E., J. Xu, and C. M. Rice. 1997. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J. Virol. 71:7187-7197.
63. Romano, P. R., S. R, Green, G. N. Barber, M. B. Mathews, and A. G. Hinnebusch. 1995. Structural requirements for double-stranded RNA binding, dimerization, and activation of the human eIF-2α kinase DAI in Saccharomyces cerevisiae. Mol. Cell. Biol. 15:365-378.
64. Ruggieri, A., T. Harada, Y. Matsuura, and T. Miyamura. 1997. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 229: 68-76.
65. Sakamuro, D., T. Furukawa, and T. Takegami. 1995. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 69:3893-3896.
66. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. New York, N.Y.
67. Samuel, C. E. 1991. Antiviral actions of interferon: interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11.
68. Sen, G. C., and P. Lengyel. 1992. The interferon system: a bird's eye view of its biochemistry. J. Biol. Chem. 267:5017-5020.
69. Sen, G. C., and R. M. Ransohoff. 1993. Interferon-induced antiviral actions and their regulation. Adv. Virus Res. 42:57-102.
70. Shukla, D. D., P. A. Hoyne, and C. W. Ward. 1995. Evaluation of complete genome sequences and sequences of individual gene products for the clas sification of hepatitis C viruses. Arch. Virol. 140:1747-1761.
71. Simmonds, P. 1995. Variability of hepatitis C virus. Hepatology 21:570-583.
72. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypep- tides expressed in Escherichia coli as fusions with glutathione-S-transferase. Gene 67:31-40.
73. IPK inhibitor. Mol. Cell. Biol. 18:2431-2443.
74. Tang, N. M., C. Y. Ho, and M. G. Katze. 1996. The 58-kDa cellular inhibitor of the double stranded RNA-dependent protein kinase requires the tetra- tricopeptide repeat 6 and DnaJ motifs to stimulate protein synthesis in vivo. J. Biol. Chem. 271:28660-28666.
75. Tanji, Y., T. Kaneko, S. Satoh, and K. Shimotohno. 1995. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69:3980- 3986.
76. Tsubota, A., K. Chayama, K. Ikeda, A. Yasuji, I. Koida, S. Saitoh, M. Hashimoto, S. Iwasaki, M. Kobayashi, and K. Hiromitsu. 1994. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 19:1088-1094.
77. Williams, B. R. G. 1995. The role of the dsRNA-activated kinase, PKR, in signal transduction. Semin. Virol. 6:191-202.
78. Zeuzem, S., J.-H. Lee, and W. K. Roth. 1997. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25:740-744.
79. Zhu, N., A. Khoshan, R. Schneider, M. Matsumoto, G. Dennert, C. F. Ware, and M. C. Lai. 1998. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF- induced apoptosis. J. Virol. 72:3691-3697.